Taxonomy

CMTA Board Approves CMT1B Project

The CMTA Board of Directors approved a new research project aimed at developing biomarkers for CMT1B to aid in the collection of natural history data critical to clinical trials.

Coronavirus (COVID-19) and CMT

The CMTA is aware that the coronavirus (COVID-19) may have more of an impact on people and families who are at higher risk of infection, so we are reaching out to share resources and ensure you are informed.

CMTA Event Schedule Update from CEO Amy Gray

The CMTA has decided to postpone and/or reschedule all upcoming CMTA branch meetings, events and walks originally scheduled to occur in March through May of 2020.

Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease

ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo; Acceleron to discontinue development of ACE-083.

Coronavirus (COVID-19) Update

The Centers for Disease Control and Prevention (CDC) is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus that was first detected in China.

CMTA Funds Cutting-Edge Gene Editing Studies for Type 2 CMT

Drs. Bruce Conklin and Luke Judge will use a $653,000 grant from the CMTA to develop the gene-editing technique known as CRISPR for application to CMT2A, 2E and 2F.

The 2020 Winter CMTA Report

Be the Change: From attitude to exercise to research, in 2020 our CMTA family is committed to be the change we want to see in the world of CMT.

David Coldiron Joins CMTA Board of Directors

The Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of David Coldiron to its Board of Directors.

A Message from Patients to Patients

As you’ll learn from watching this video by two young members of our CMT family, tiredness, exhaustion, fatigue and “sluggishness” are all part of having CMT.

Another $500,000 Pledge to Type 2 Research!

Bruce Chizen, a special advisor to the Board of Directors, will match donations to CMT2 research on a one-to-one basis, up to $500,000.